# 1 Complement 3a Receptor 1 on Macrophages and Kupffer cells is not required for the

# 2 Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease

- 3
- 4 Edwin A. Homan<sup>1</sup>, Ankit Gilani<sup>1</sup>, Alfonso Rubio-Navarro<sup>1</sup>, Maya Johnson<sup>1</sup>, Eric Cortada<sup>1</sup>, Renan
- 5 Pereira de Lima<sup>1</sup>, Lisa Stoll<sup>1</sup>, James C. Lo<sup>1\*</sup>.
- 6

# 7 Affiliations:

- <sup>1</sup> Division of Cardiology, Department of Medicine, Cardiovascular Research Institute, Weill
- 9 Center for Metabolic Health, Weill Cornell Medicine, New York, New York, 10021
- 10 \*Corresponding author. Email: jlo@med.cornell.edu.
- 11
- 12
- 13

### 14 Abstract

15 Together with obesity and type 2 diabetes, metabolic dysfunction-associated steatotic liver 16 disease (MASLD) is a growing global epidemic. Activation of the complement system and 17 infiltration of macrophages has been linked to progression of metabolic liver disease. The role of 18 complement receptors in macrophage activation and recruitment in MASLD remains poorly 19 understood. In human and mouse, C3AR1 in the iver is expressed primarily in Kupffer cells, but 20 is downregulated in humans with MASLD compared to obese controls. To test the role of 21 complement 3a receptor (C3aR1) on macrophages and liver resident macrophages in MASLD, 22 we generated mice deficient in C3aR1 on all macrophages (C3aR1-M<sub>0</sub>KO) or specifically in 23 liver Kupffer cells (C3aR1-KpKO) and subjected them to a model of metabolic steatotic liver 24 disease. We show that macrophages account for the vast majority of C3ar1 expression in the 25 liver. Overall, C3aR1-MoKO and C3aR1-KpKO mice have similar body weight gain without 26 significant alterations in glucose homeostasis, hepatic steatosis and fibrosis, compared to 27 controls on a MASLD-inducing diet. This study demonstrates that C3aR1 deletion in 28 macrophages or Kupffer cells, the predominant liver cell type expressing C3aR1, has no 29 significant effect on liver steatosis, inflammation or fibrosis in a dietary MASLD model. 30 31 Keywords: obesity, hepatic steatosis, steatohepatitis, C3aR1, macrophage, Kupffer cell

#### 33 Introduction

34 Obesity and related metabolic diseases such as type 2 diabetes (T2D) and metabolic 35 dysfunction-associated steatotic liver disease (MASLD) remain a worldwide epidemic with 36 increasing prevalence<sup>1,2</sup>. MASLD describes the constellation of hepatic lipid deposition, 37 inflammation, and fibrosis associated with obesity and T2D that ultimately leads to MASH 38 cirrhosis, which has become the leading cause of liver transplantation in the United States<sup>3-6</sup>. 39 Notably, MASLD is increasingly recognized as an important risk-enhancing factor for 40 atherosclerotic cardiovascular disease<sup>7,8</sup>.

41 Liver macrophages help to maintain hepatic homeostasis and consist of embryo-derived 42 resident macrophages called Kupffer cells, which self-renew and do not migrate, or peripheral 43 monocyte-derived macrophages, which infiltrate into liver tissue upon metabolic or toxic liver injury and under certain circumstances can take on Kupffer cell-like identity<sup>9-13</sup>. In obesity, bone 44 45 marrow-derived myeloid cells migrate to the steatotic liver, and pro-inflammatory recruited macrophages are postulated to drive the progression of MASLD to MASH<sup>14</sup>. Spatial 46 47 proteogenomics reveals a population of lipid-associated macrophages near bile canaliculi that is 48 induced by local lipid exposure and drives fibrosis in steatotic regions of murine and human liver<sup>15</sup>. In addition, deep transcriptomic profiling in human MASLD has identified candidate gene 49 signatures for steatohepatitis and fibrosis with possible therapeutic implications<sup>16</sup>. 50

51 Activation of the body's complement system leads to increased cell lysis, phagocytosis, 52 and inflammation<sup>17</sup>, and it is increasingly recognized as an important contributor to regulation of metabolic disorders such as T2D and MASLD<sup>18,19</sup>. In human liver biopsies, higher lobular 53 54 inflammation scores correlate with activation of the complement alternative pathway<sup>20</sup>, which can signal *via* the C3a receptor 1 (C3aR1), a G<sub>i</sub>-coupled G protein-coupled receptor<sup>21</sup>. The 55 56 complement 3 polypeptide (C3) is cleaved by C3 convertase to the activated fragment, C3a, which then binds C3aR1<sup>22</sup>. Complement factor D (CFD), also known as the adipokine adipsin, is 57 the rate-limiting step in the alternative pathway of complement activation<sup>23,24</sup>. 58

59	Several studies have reported opposing roles of adipsin and C3aR1 on hepatic steatosis
60	in diet-induced obesity <sup>25-27</sup> . Our lab has found that adipsin/CFD is critical for maintaining
61	pancreatic beta cell mass and function <sup>28,29</sup> . Murine obese and diabetic models such as $db/db$
62	mice and high fat diet (HFD) feeding result in very low circulating adipsin <sup>23</sup> . Replenishing adipsin
63	in <i>db/db</i> mice raises levels of C3a and insulin, lowers blood glucose levels, and inhibits hepatic
64	gluconeogenesis <sup>28</sup> . However, whole-body deletion of C3aR1 decreases macrophage infiltration
65	and activation in adipose tissue, protects from HFD-induced obesity and glucose intolerance,
66	and decreases hepatic steatosis and inflammation <sup>30</sup> . In a model of fibrosing steatohepatitis,
67	bone marrow-derived macrophages were found to activate hepatic stellate cells, which was
68	blunted in whole-body C3aR1 KO mice <sup>31</sup> .
69	In the present study we aim to explore the macrophage-specific effect of complement
70	receptor signaling in MASLD pathogenesis. To determine the consequences of macrophage and
71	Kupffer cell ablation of C3aR1, we use a murine dietary model of MALFD/MASH, the Gubra
72	Amylin Nash (GAN) diet, which has macronutrient similarities to the Western diet and produces
73	similar histologic and transcriptomic changes to human MASLD/MASH <sup>32-34</sup> .
74	
75	Results
76	C3AR1 is expressed in human and mouse liver, primarily in Kupffer cells.
77	In the scRNA-Seq database, Human Protein Atlas, C3AR1 is broadly expressed
78	throughout the body, with increased abundance in tissues rich in immunologic cell types, such
79	as bone marrow and appendix (Fig. 1A) <sup>35</sup> . In a single-cell transcriptomic database of healthy
80	human liver, C3AR1 expression predominates in the macrophage and Kupffer cell population,
81	with minimal-to-undetectable C3AR1 expression in hepatocytes or hepatic stellate cells by
82	scRNA-Seq (Fig. 1B) <sup>36</sup> . In the mouse liver scRNA-Seq database, Tabula Muris, <i>C3ar1</i> is
83	similarly expressed primarily in Kupffer cells (Fig. S1) <sup>37</sup> .
84	

# 85 Hepatic CFD and C3AR1 are downregulated in human MASLD/MASH.

86	We also examined data from Suppli and coworkers, who performed bulk transcriptomic
87	analysis of human liver samples from an age-matched cohort of healthy controls and obese
88	controls without MASLD, as well as MASLD and MASH patients without cirrhosis <sup>38</sup> . Both <i>CFD</i>
89	and C3AR1 were unchanged in obese subjects without MASLD compared to healthy controls,
90	but both CFD and C3AR1 were significantly downregulated in liver biopsies from both MASLD
91	and MASH patients compared to both healthy controls and obese subjects without MASLD (Fig.
92	1C). Interestingly, both CFD and C3AR1 levels were slightly higher in MASH individuals
93	compared to those with MASLD only.
94	
95	Murine MASH model recapitulates key features of human MASH
96	At 5 weeks of age, we subjected C3ar1 flox/flox control mice to standard regular diet
97	(RD) or GAN diet I <sup>32,33</sup> . After 28 weeks of GAN diet, male mice gained body weight compared to
98	RD (Fig. 1D), primarily as fat mass (Fig. S2-3), but weight gain in female GAN-fed mice was
99	attenuated. Histologic signs of MASLD were present in GAN-fed mice (Fig. 1E), most notably
100	hepatic steatosis and hepatocyte ballooning (Fig. 1F), and liver fibrosis measured by collagen
101	deposition nearly doubled with GAN compared to RD (Fig. 1G). Both hepatic C3ar1 and Cfd
102	gene expression were robustly increased on GAN compared to RD, as were markers of
103	macrophage infiltration, hepatic inflammation, and fibrosis, including collagen gene expression,
104	indicating progression to fibrotic MASH (Fig. 1H).
105	
106	Macrophage-specific C3aR1 deletion does not alter glucose homeostasis.
107	Owing to the differential regulation of the C3AR1 gene in MASLD between mice and
108	humans, we generated transgenic mice with macrophage-specific deletion of C3aR1 (C3aR1-
109	$M\phi KO$ ) to target both liver resident macrophages and recruited monocytes. Successful deletion
110	of C3ar1 in macrophages from the C3aR1-M $_{\phi}$ KO mouse was confirmed by quantitative RT-

111 PCR of isolated peritoneal macrophages that were F4/80+ and CD68+ by fluorescence-

activated cell sorting (Fig. 2A). In liver tissue, *C3ar1* expression was reduced by ~88% in both

male and female C3aR1-M $\phi$ KO (Fig. 2B). These results indicate that macrophages account for

114 the vast majority of *C3ar1* expression in the liver.

115 When placed on GAN diet, there was no significant difference in weight gain between 116 control and C3aR1-M<sub>0</sub>KO mice (Fig. 2C). There was similarly no difference in percent lean or 117 fat mass between these mice (Fig. 2D). Glucose tolerance tests performed in fasted mice after 118 27 weeks GAN diet found no significant differences between control and C3aR1-M0KO mice 119 (Fig. 2E). There was also no difference in insulin sensitivity as measured by insulin tolerance 120 tests in male mice (Fig. S4). Insulin resistance as measured by comparing the ratio of fasting 121 glucose level to fasting insulin level (HOMA-IR) was also unchanged between controls and 122 C3aR1-MoKO mice (Fig. S5). Circulating serum ALT levels were unchanged in male control and 123 C3aR1-M<sub>0</sub>KO mice on GAN diet (Fig. S6).

124

125 Macrophage-specific C3aR1 deletion does not significantly impact hepatic steatosis or fibrosis.

126 Liver samples collected after 28-30 weeks of GAN or regular diet did not show significant 127 differences in liver mass between control and C3aR1-M@KO mice (Fig. 2F). Male mice on GAN 128 diet developed similar qualitative appearance on histology (Fig. 2G), and slide image analysis 129 showed similar proportions of lipid droplet area and collagen area (Figs. 2H, 2I). This indicates 130 that there were no significant differences in steatosis or fibrosis between GAN-fed control and 131 C3aR1-M<sub>0</sub>KO male mice. While C3ar1 expression was markedly reduced in the C3aR1-M<sub>0</sub>KO 132 liver tissue (Fig. 2B), there were no detectable gene expression changes in markers of fibrosis, 133 inflammation, or lipid handling (Fig. 2J). Similarly, in female mice there were also no significant 134 differences between control and C3aR1-MoKO mouse liver in a subset of key gene markers of 135 fibrosis or inflammation (Fig. S7).

136

137	Kupffer cell-specific C3aR1 deletion does not alter weight gain or glucose homeostasis.
138	To explore whether there may be competing effects between recruited monocytes and
139	liver resident macrophages (Kupffer cells), we next generated Kupffer cell-specific C3aR1
140	knockout mice (C3aR1-KpKO) and fed them GAN diet. Body weight gain was similar between
141	genotypes for both male and female mice (Fig. 3A), and there was no difference in body
142	composition between control and C3aR1-KpKO mice on GAN diet (Fig. 3B). There was similarly
143	no significant difference in glucose homeostasis between the genotypes during a glucose
144	tolerance test (Fig. 3C).
145	
146	Kupffer cell-specific C3aR1 deletion does not significantly impact hepatic steatosis or fibrosis.
147	Liver mass was not significantly different between control and C3aR1-KpKO mice on
148	GAN diet (Fig. 3D). Liver sections appeared qualitatively similar by histology stained with
149	Masson's trichrome (Fig. 3E). There were similar levels of hepatic steatosis in these mice as
150	measured by percent lipid droplet area (Fig. 3F). When measured by collagen proportional area,
151	there was no significant differences in liver fibrosis between C3aR1-KpKO and control mice
152	(Fig. 3G). While C3ar1 expression was reduced by 73% in liver tissue of C3aR1-KpKO mice,
153	there were no significant differences in expression of inflammatory, fibrotic, or lipid handling
154	gene markers (Fig. 3H). C3ar1 expression similarly decreased by ~90% in liver tissue of female
155	C3aR1-KpKO mice fed regular diet compared to control mice (Fig. S8). These data also indicate
156	that Kupffer cells account for ~80% of hepatic <i>C3ar1</i> gene expression in our mouse model of
157	MASLD/MASH.
158	
159	Discussion

Overall, we found that macrophage or Kupffer cell expression of *C3ar1* does not impact
body weight gain or histologic/transcriptomic features of MASLD/MASH in a murine dietary

model. Deletion of C3aR1 in the macrophage population throughout the body, or specifically in
Kupffer cells, did not affect weight gain, glucose homeostasis, or extent of hepatic
steatosis/fibrosis.

165 Our findings in macrophage-specific C3aR1 KO mice contrast with prior observations in whole-body C3aR1 KO mice<sup>30</sup>, which are protected from diet-induced obesity, have improved 166 167 glucose tolerance, and exhibit decreased hepatic steatosis. In both our macrophage- and 168 Kupffer cell-specific C3aR1 KO mice, which had similar degrees of obesity compared to 169 controls, there was no detectable effect on liver steatosis or fibrosis despite the near abrogation 170 of C3ar1 expression. This raises the possibility that the lower levels of hepatic steatosis and 171 insulin resistance previously observed in the whole body C3aR1 KO mice may be secondary to 172 protection from obesity. Protection from diet-induced obesity in whole-body C3aR1 KO mice 173 may be mediated by a non-macrophage cell type, since our macrophage-specific C3aR1 KO 174 mice were not afforded this protection. The C3ar1-expressing cell types that promote obesity 175 and MASLD remains to be determined.

Our laboratory recently reported sex-dependent regulation of thermogenic adipose tissue mediated by adipocyte-derived C3aR1<sup>39</sup>. However, no such sexual dimorphism was observed in hepatic expression of key MASH genes in response to GAN diet in our macrophage- or Kupffer cell-specific C3aR1-deficient mice. Other work has suggested possible compensatory effects from its sister anaphylatoxin receptor C5aR1, with increased cold-induced adipocyte browning and attenuated diet-induced obesity seen in C3aR1/C5aR1 double KO mice<sup>40</sup>.

The strengths of our study include careful metabolic and transcriptomic phenotyping of cell type-specific transgenic mice. Some limitations were our use of a single MASLD dietary model and our focus on the C3aR1 pathway. While the GAN diet recapitulates many features of human MASH due to its similarity to Western diet<sup>34</sup>, relatively low levels of fibrosis were seen in our study, potentially related to initiating the diet at young age; more rapid fibrosis induction has

been seen when GAN diet is initiated at older ages<sup>41</sup>. Lastly, while C3AR1/C3ar1 expression is 188 189 very low in non-macrophage cells (Fig. B, S1), C3aR1 signaling on other hepatic cell types not 190 explored in this study, such as hepatic stellate cells, could mediate the observed effect in the 191 whole-body C3aR1 KO mouse. 192 Deletion of C3aR1 in macrophages generally, or in liver resident macrophages 193 specifically, had no major effect on systemic glucose homeostasis and hepatic steatosis, 194 inflammation, and fibrosis in this murine dietary model of MASLD/MASH. The complement 195 system is a complex entity directing an important part of the body's inflammatory and tissue 196 repair response in MASLD. Further work is needed to elucidate the mechanisms of the role of 197 C3aR1 in the pathogenesis of MASH and cirrhosis. 198

#### 199 Materials and Methods

200 Animals

*C3ar1 flox/flox* mice were on the C57BL/6J background as described<sup>42</sup>. Homozygous 201 202 LysM-Cre mice on the C57BL/6J background were purchased from Jackson Laboratories 203 (Strain #004781). C3ar1 flox/flox homozygous mice were used in the experiments as controls from the same backcross generation<sup>39</sup>. All mice were maintained in plastic cages under a 204 205 12h/12h light/dark cycle at constant temperature (22°C) with free access to water and food. 206 Mice were fed regular diet containing 4.5%kcal fat PicoLab Rodent diet 20 (LabDiet) or GAN 207 diet containing 40%kcal HFD (mostly palm oil) with 20% fructose and 2% cholesterol 208 (D09100310, Research Diets) for 28-30 weeks. Fat mass and lean mass were determined via 209 noninvasive 3-in-1 body composition analyzer (EchoMRI). Mice were humanely euthanized with 210  $CO_2$  inhalation followed by exsanguination by cardiac puncture.

211

212 Blood chemistry and serum insulin analysis

213 Mice were fasted overnight (14-16 hours) for glucose tolerance tests and injected 214 intraperitoneally with syringe-filtered D-glucose solution (2g/kg). For insulin tolerance test, mice 215 were fasted for 6 hours and injected with 0.5 mIU/kg insulin. Blood glucose levels were assayed 216 by commercial glucometer (OneTouch) by tail vein blood samples. Plasma insulin levels were 217 measured from mice fasted for 6 hours. Tail vein blood was collected into lithium heparin-coated 218 tubes, centrifuged at 2000xg at 4°C, and plasma insulin levels were determined by ELISA using 219 a standard curve (Mercodia). Serum alanine aminotransferase levels were measured in serum 220 from blood collected via cardiac puncture using a commercially available colorimetric assay 221 (TR71121, ThermoFisher Scientific).

222

#### 223 Peritoneal macrophage isolation and flow cytometry

224 Peritoneal macrophages were isolated from as previously described<sup>43</sup>. Briefly, mice 225 were euthanized then immediately injected intraperitoneally with 10 mL phosphate-buffered 226 saline (PBS, pH 7.4) at room temperature. After a 3-5 minute incubation period, peritoneal fluid 227 was removed with sterile needle and syringe and placed on ice. After centrifugation at 300xg, 228 the pellet was resuspended in PBS containing 2% fetal bovine serum and 0.1% sodium azide. 229 Cells were stained with phycoerythrin-conjugated anti-F4/80 (clone BM8, cat. #123110) and 230 fluorescein isothiocyanate-conjugated anti-CD11b (clone M1/70, cat. #101206) fluorescent 231 antibodies (Biolegend). Stained cells were loaded on MA900 fluorescence-activated cell sorter 232 (Sony), and dual-positive F480+/CD11b+ cells were sorted for subsequent RNA extraction.

233

#### 234 Histological studies

A mid-distal portion of the left liver lobe was fixed with 10% buffered formalin and
transferred to 70% ethanol. Samples were embedded in paraffin, sectioned at ~5μm thickness,
and stained with Masson's trichrome. Slides were imaged using Zeiss Axioscan7 at 20x
magnification. Histologic analyses were performed using ImageJ software (version 1.53t). Lipid

239	droplet area was quantified by subtracting non-droplet area in the green channel from total
240	section area of 2-3 independent sections. Collagen proportionate area was quantified by
241	measuring total area in the red channel after reducing intensity threshold to 60-70.
242	
243	RNA extraction and real-time quantitative PCR analysis
244	Total RNA from liver tissue lysates was extracted using Trizol reagent (Invitrogen)
245	followed by RNAeasy Mini kit (Qiagen) as per manufacturer's protocol. RNA was reverse-
246	transcribed using the High Capacity cDNA RT kit (Thermo). Quantitative PCR was performed
247	using SYBR Green Master Mix (Quanta) and specific gene primers on QuantStudio6 Flex Real-
248	Time PCR Systems (Thermo Fisher Scientific) using the delta-delta Ct method. Expression
249	levels were normalized to Ribosomal protein S18 ( <i>Rps18</i> ). Primer sequences are listed in
250	Supplementary Table A.
251	
252	Statistical analyses
253	All statistical analyses were performed using GraphPad Prism10. Unpaired two-tailed
254	Student's t test with Welch correction for most analyses, with Holm-Šídák correction for multiple
255	comparisons where applicable, and p<0.05 was considered statistically significant.
256	
257	Funding
258	E.A.H. was supported by NIH T32 5T32HL160520-02. A.G. was supported by was
259	supported by ADA 9-22-PDFPM-01. R.P.L was supported by AHA 23DIVSUP1074485. L.S. was
260	supported by AHA 908952 and an Ehrenkranz Young Scientist Award. J.C.L. was supported by
261	NIH R01 DK121140, R01 DK121844, and R01 DK132879. The views expressed in this
262	manuscript are those of the authors and do not necessarily represent the official views of the
263	American Diabetes Association, the American Heart Association, the National Institute of

264 Diabetes and Digestive and Kidney Diseases, or the National Institutes of Health.

### 265

### 266 Acknowledgments

- 267 We would like to thank Dr. Baran Ersoy, Dr. Robert Schwartz, and Dr. Saloni Sinha for their
- technical advice and assistance.

269

- 270 Declaration of Competing Interest
- 271 None
- 272
- 273 Data Availability
- 274 Data will be made available upon reasonable request.

#### 276 Figure Legends

277

### 278 Figure 1. C3AR1 is found in macrophages, is modulated by MASLD/MASH in humans,

#### and is induced by a murine dietary model of MASH.

- A) Relative C3AR1 human tissue expression level by tissue, derived from deep sequencing
- of the mRNA combined dataset (HPA and GTEx) in the Human Protein Atlas, shown as
- 282 normalized transcripts per million (nTPM). Liver is highlighted in purple and immunologic
  283 tissues are highlighted in red.
- B) Single-cell RNA sequencing distribution of C3AR1 expression in human liver (tSNE, t-
- 285 distributed Stochastic Neighbor Embedding).
- 286 C) Analysis of *CFD* and *C3AR1* expression from liver biopsy samples in patients with
- 287 MASH, MASLD, obesity without MASLD, and age-matched healthy controls (n = 12-16
- 288 per group, Welch *t* test with Holm-Šídák correction for multiple comparisons).
- D) Weight curve in male and female flox/flox control mice placed on GAN high-fat diet

290 compared to regular diet (RD) controls (males, n = 7; females, n = 6).

- E) Representative liver section staining by Masson's Trichrome in male control mice on RD
   or GAN diet for 28 weeks (scale bar = 100 mm).
- F) Lipid droplet area quantification in liver sections from male control mice, excluding
  vessel lumens (RD, n = 3; GAN, n = 7).
- G) Collagen area quantification in liver sections of male control mice (RD, n = 3; GAN, n =
  7).
- H) Gene expression of key macrophage or fibrosis genes in male control mice on GAN or
   RD (n = 6 per group).

Unpaired two-tailed Student's *t* test (Except 1C as above). Annotations: \*, p < 0.05; \*\*, p < 0.01;</li>
\*\*\*, p < 0.001</li>

#### 301 Figure 2. C3aR1 deletion in all macrophages does not affect weight gain, glucose

#### 302 homeostasis, liver steatosis or fibrosis.

303	A)	Expression of C3ar1	in isolated peritoneal F4/80+/CD68	+ cells from flox/flox control mice
-----	----	---------------------	------------------------------------	-------------------------------------

304 (n = 6) or C3aR1-M $\phi$ KO male mice (n = 3).

- B) Expression of C3ar1 in whole liver from control or C3aR1-M $\phi$ KO mice (n = 11-12 per
- 306 male group, n = 13-14 per female group).
- 307 C) Body mass curve of control or C3aR1-M $\phi$ KO mice on GAN high-fat diet starting at 5

308 weeks of age (n = 11-12 per male group, n = 14 per female group).

D) Body composition analysis by EchoMRI in control or C3aR1-MφKO mice after 30 weeks

GAN diet (n = 
$$6-9$$
 per male group, n =  $9-13$  per female group).

311 E) Glucose tolerance test in control or C3aR1-M $\phi$ KO mice with 14h fast after 28 weeks

312 GAN diet (n = 6-9 per male group, n = 9-14 per female group).

F) Liver mass in control or C3ar1-MφKO male mice at time of euthanasia after 30 weeks

GAN diet (n = 6-9 per male group, n = 9-14 per female group).

G) Representative liver section staining by Masson's Trichrome in male control or C3ar1-

316  $M\phi KO$  mice (scale bar = 100 mm).

- 317 H) Lipid droplet area in liver sections from male control or C3ar1-M $\phi$ KO mice, excluding 318 vessel lumens (n = 6-7 per group).
- 319 I) Collagen area in liver sections from male control or C3ar1-M $\phi$ KO mice (n = 6-7 per 320 group)
- J) Relative fold expression of key gene markers for fibrosis, inflammation, and liver
- 322 metabolism in whole liver from male control or C3ar1-MφKO mice mice after 30 weeks

323 GAN diet (n = 11-12 per group).

324 Unpaired two-tailed Student's *t* test: Student's *t* test: \*, p < 0.05.

# 326 Figure 3. C3aR1 deletion in Kupffer cells does not affect weight gain, glucose

#### 327 homeostasis, liver steatosis or fibrosis.

328	A) Body mass curve on GAN diet in flox/flox control or C3aR1-KpKO mice beginning at 5
329	weeks of age (n = 8-10 per group).
330	B) Body composition analysis by EchoMRI in control or C3aR1-KpKO mice after 28 weeks
331	GAN diet (n = 8-10).
332	C) Glucose tolerance test in control or C3aR1-KpKO mice with 14h fast after 26 weeks
333	GAN diet (n = 8-10).
334	D) Liver mass in control or C3aR1-KpKO male mice at time of euthanasia after 30 weeks
335	GAN diet (n = 8-10).
336	E) Representative liver section staining by Masson's Trichrome in control or C3aR1-KpKO
337	male mice (scale bar = 100 mm).
338	F) Lipid droplet area quantified on liver sections of control or C3aR1-KpKO male mice ,
339	excluding vessel lumens (n = 8-9).
340	G) Collagen area quantified on whole liver section of control or C3aR1-KpKO male mice (n=
341	8-9).
342	H) Relative gene expression in male control or C3aR1-KpKO mice after 30 weeks GAN diet
343	(n = 5-6).
344	Unpaired two-tailed Student's <i>t</i> test: **, $p < 0.01$ .
0.45	

## 346 Supplementary figures.

347 S1) Single cell RNA sequencing analysis of *C3ar1* expression in mouse liver tissue (see

348 text).

- 349 S2) Percent lean and fat mass of flox/flox control mice after 20 weeks of GAN or RD diet (n =
- 350 6-7 per group).
- 351 S3) Absolute lean and fat mass of flox/flox control mice after 20 weeks of GAN or RD diet (n
- 352 = 6-7 per group).
- 353 S4) Insulin tolerance test in control or C3aR1-MφKO male mice with 14h fast after 29 weeks
- 354 GAN diet (n = 6-9 per group).
- 355 S5) HOMA-IR measurement of insulin resistance in control or C3aR1-MφKO mice with 6h
- fast after 27 weeks GAN diet (n = 6-9 per male group, n = 9-13 per female group).
- 357 S6) Serum alanine aminotransferase levels in control or C3aR1-MφKO male mice after 30
- 358 weeks GAN diet (n = 4 per group).
- 359 S7) Relative gene expression in control or C3aR1-M $\phi$ KO female mice after 30 weeks GAN
- 360 diet (n = 13-14 per group).
- 361 S8) Relative *C3ar1* expression in control or C3aR1-KpKO female mice after 30 weeks RD
- 362 diet (n = 2-3 per group).
- 363 Unpaired two-tailed Student's t test: \*\*, p < 0.01; \*\*\*, p < 0.001.
- 364





Figure 1. C3AR1 is found in macrophages, is modulated by MASLD/MASH in humans, and is induced by a murine dietary model of MASH.

- A) Relative C3AR1 human tissue expression level by tissue, derived from deep sequencing of the mRNA combined dataset (HPA and GTEx) in the Human Protein Atlas, shown as normalized transcripts per million (nTPM). Liver is highlighted in purple and immunologic tissues are highlighted in red.
- B) Single-cell RNA sequencing distribution of C3AR1 expression in human liver (tSNE, t-distributed Stochastic Neighbor Embedding).
- C) Analysis of CFD and C3AR1 expression from liver biopsy samples in patients with MASH, MASLD, obesity without MASLD, and age-matched healthy controls (n = 12-16 per group, Welch t test with Holm-Šídák correction for multiple comparisons).
- D) Weight curve in male and female flox/flox control mice placed on GAN high-fat diet compared to regular diet (RD) controls (males, n = 7; females, n = 6).
- E) Representative liver section staining by Masson's Trichrome in male control mice on RD or GAN diet for 28 weeks (scale bar = 100 ∝m).
- F) Lipid droplet area quantification in liver sections from male control mice, excluding vessel lumens (RD, n = 3; GAN, n = 7).
- G) Collagen area quantification in liver sections of male control mice (RD, n = 3; GAN, n = 7).
- H) Gene expression of key macrophage or fibrosis genes in male control mice on GAN or RD (n = 6 per group).
- Unpaired two-tailed Student's t test (Except 1C as above). Annotations: \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001.




#### 368 369

Figure 2. C3aR1 deletion in all macrophages does not affect weight gain, glucose homeostasis, liver steatosis or fibrosis.

- A) Expression of C3ar1 in isolated peritoneal F4/80+/CD68+ cells from flox/flox control mice (n = 6) or C3aR1-Mj KO male mice (n = 3).
- B) Expression of C3ar1 in whole liver from control or C3aR1-Mj KO mice (n = 11-12 per male group, n = 13-14 per female group).
- C) Body mass curve of control or C3aR1-Mj KO mice on GAN high-fat diet starting at 5 weeks of age (n = 11-12 per male group, n = 14 per female group).
- D) Body composition analysis by EchoMRI in control or C3aR1-Mj KO mice after 30 weeks GAN diet (n = 6-9 per male group, n = 9-13 per female group).
- E) Glucose tolerance test in control or C3aR1-Mj KO mice with 14h fast after 28 weeks GAN diet (n = 6-9 per male group, n = 9-14 per female group).
- F) Liver mass in control or C3ar1-Mj KO male mice at time of euthanasia after 30 weeks GAN diet (n = 6-9 per male group, n = 9-14 per female group).
- G) Representative liver section staining by Masson's Trichrome in male control or C3ar1-Mj KO mice (scale bar = 100 orm).
- H) Lipid droplet area in liver sections from male control or C3ar1-Mj KO mice, excluding vessel lumens (n = 6-7 per group).
- I) Collagen area in liver sections from male control or C3ar1-Mj KO mice (n = 6-7 per group)
- J) Relative fold expression of key gene markers for fibrosis, inflammation, and liver metabolism in whole liver from male control or C3ar1-Mj KO mice mice after 30 weeks GAN diet (n = 11-12 per group).
- Unpaired two-tailed Student's *t* test: Student's *t* test: \*,  $\dot{p} < 0.05$ .

# Figure 3.



371 372

#### Figure 3. C3aR1 deletion in Kupffer cells does not affect weight gain, glucose homeostasis, liver steatosis or fibrosis.

A) Body mass on GAN diet in flox/flox control or C3aR1-KpKO mice beginning at 5 weeks of age (n = 8-10 per group).

B) Body composition analysis by EchoMRI in control or C3aR1-KpKO mice after 28 weeks GAN diet (n = 8-10).

C) Glucose tolerance test in control or C3aR1-KpKO mice with 14h fast after 26 weeks GAN diet (n = 8-10).

D) Liver mass in control or C3aR1-KpKO male mice at time of euthanasia after 28 weeks GAN diet (n = 8-10).


E) Representative liver section staining by Masson's Trichrome in control or C3aR1-KpKO male mice (scale bar = 100 am).

F) Lipid droplet area quantified on liver sections of control or C3aR1-KpKO male mice, excluding vessel lumens (n = 8-9).

G) Collagen area quantified on whole liver section of control or C3aR1-KpKO male mice (n= 8-9).

H) Relative gene expression in control or C3aR1-KpKO male mice after 30 weeks GAN diet (n = 5-6).

Unpaired two-tailed Student's *t* test: \*\*, p < 0.01.



374 375

#### Supplementary figures.

S1) Single cell RNA sequencing analysis of *C3ar1* expression in mouse liver tissue (see text).

S2) Percent lean and fat mass of flox/flox control mice after 20 weeks of GAN or RD diet (n = 6-7 per group).

S3) Absolute lean and fat mass of flox/flox control mice after 20 weeks of GAN or RD diet (n = 6-7 per group).

S4) Insulin tolerance test in control or C3aR1-Mj KO male mice with 14h fast after 29 weeks GAN diet (n = 6-9 per group).

S5) HOMA-IR measurement of insulin resistance in control or C3aR1-Mj KO mice with 6h fast after 27 weeks GAN diet (n =

6-9 per male group, n = 9-13 per female group).

S6) Serum alanine aminotransferase levels in control or C3aR1-Mj KO male mice after 30 weeks GAN diet (n = 4 per group).

S7) Relative gene expression in control or C3aR1-Mj KO female mice after 30 weeks GAN diet (n = 13-14 per group).

S8) Relative C3ar1 expression in control or C3aR1-KpKO female mice after 30 weeks RD diet (n = 2-3 per group).

Unpaired two-tailed Student's *t* test: \*\*, p < 0.01; \*\*\*, p < 0.001.

# 377 Supplementary Table S1.

<i>Mus musculus</i> gene name	Forward qPCR primer	Reverse qPCR primer
Acc2	GCCTCCACTCACATTGGTTT	ATTGAAGAAAGCTGGGCTGA
Acta2	GGCTCTGGGCTCTGTAAGG	CTCTTGCTCTGGGCTTCATC
Adgre1	TGCATCTAGCAATGGACAGC	GCCTTCTGGATCCATTTGAA
C3ar1	TGACAGGTCAGCTCCTTCCT	CATTAGGAGGCTTTCCACCA
Ccr2	ATCCACGGCATACTATCAACATC	CAAGGCTCACCATCATCGTAG
Cd163	TCCACACGTCCAGAACAGTC	CCTTGGAAACAGAGACAGGC
Cfd	CGTACCATGACGGGGTAGTC	ATCCGGTAGGATGACACTCG
Col1a1	GTGCTCCTGGTATTGCTGGT	GGCTCCTCGTTTTCCTTCTT
Col1a2	GCCACCATTGATAGTCTCTCC	CACCCCAGCGAAGAACTCATA
Col3a1	GGGTTTCCCTGGTCCTAAAG	CCTGGTTTCCCATTTTCTCC
Fasn	TTGCTGGCACTACAGAATGC	AACAGCCTCAGAGCGACAAT
Fgf21	CTGCTGGGGGTCTACCAAG	CTGCGCCTACCACTGTTCC
Hnf1a	GACCTGACCGAGTTGCCTAAT	CCGGCTCTTTCAGAATGGGT
ll1b	CTGGTGTGTGACGTTCCCATTA	CCGACAGCACGAGGCTTT
116	ACAACCACGGCCTTCCCTACTT	CACGATTTCCCAGAGAACATGTG
Pepck1	TCATCATCACCCAAGAGCAG	CACATAGGGCGAGTCTGTCA
Rps18	CATGCAGAACCCACGACAGTA	CCTCACGCAGCTTGTTGTCTA
Scd1	CGCCCAAGCTGGAGTACGTC	CGCCCAAGCTGGAGTACGTC
Srebp1c	CTGGCAGTTCCATTGACAAG	ACTGAAGCTGGTGACTGCTG
Tgfb1	TGCGCTTGCAGAGATTAAAA	AGCCCTGTATTCCGTCTCCT
Tlr4	TGTCATCAGGGACTTTGCTG	GGACTCTGATCATGGCACTG
Tnfa	ACGGCATGGATCTCAAAGAC	AGATAGCAAATCGGCTGACG
Trem2	CTACCAGTGTCAGAGTCTCCGA	CCTCGAAACTCGATGACTCCTC

#### 379 References

- Ge, X., Zheng, L., Wang, M., Du, Y. & Jiang, J. Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study. *BMJ Open* **10**, e036663 (2020). <u>https://doi.org:10.1136/bmjopen-</u> 2019-036663
- Younossi, Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors
  and prevention. Nat Rev Gastroenterol Hepatol 15, 11-20 (2018).
  https://doi.org:10.1038/nrgastro.2017.109
- 387 3
   388 Ferguson, D. & Finck, B. N. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. *Nat Rev Endocrinol* **17**, 484-495 (2021).
   389 https://doi.org:10.1038/s41574-021-00507-z
- Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of
  NAFLD development and therapeutic strategies. *Nat Med* 24, 908-922 (2018).
  https://doi.org:10.1038/s41591-018-0104-9
- 3935Stefan, N., Haring, H. U. & Cusi, K. Non-alcoholic fatty liver disease: causes, diagnosis,394cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 7,395313-324 (2019). https://doi.org:10.1016/S2213-8587(18)30154-2
- 3966Kim, H. *et al.* Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From397NAFLD to NASH to HCC. Int J Mol Sci 22 (2021). <a href="https://doi.org/10.3390/ijms22094495">https://doi.org/10.3390/ijms22094495</a>
- Duell, P. B. *et al.* Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific
  Statement From the American Heart Association. *Arterioscler Thromb Vasc Biol* 42,
  e168-e185 (2022). <u>https://doi.org:10.1161/ATV.00000000000153</u>
- 4018Kasper, P. et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol402110, 921-937 (2021). https://doi.org:10.1007/s00392-020-01709-7
- Barreby, E., Chen, P. & Aouadi, M. Macrophage functional diversity in NAFLD more
  than inflammation. *Nat Rev Endocrinol* 18, 461-472 (2022).
  <u>https://doi.org:10.1038/s41574-022-00675-6</u>
- 40610Cai, J., Zhang, X. J. & Li, H. The Role of Innate Immune Cells in Nonalcoholic407Steatohepatitis. *Hepatology* **70**, 1026-1037 (2019). <a href="https://doi.org/10.1002/hep.30506">https://doi.org/10.1002/hep.30506</a>
- 408
   11
   Guilliams, M. & Scott, C. L. Liver macrophages in health and disease. Immunity 55, 1515-1529 (2022). <a href="https://doi.org/10.1016/j.immuni.2022.08.002">https://doi.org/10.1016/j.immuni.2022.08.002</a>
- 410 12 Park, S. J., Garcia Diaz, J., Um, E. & Hahn, Y. S. Major roles of kupffer cells and
  411 macrophages in NAFLD development. *Front Endocrinol (Lausanne)* 14, 1150118 (2023).
  412 <u>https://doi.org:10.3389/fendo.2023.1150118</u>
- 413 13 Sakai, M. *et al.* Liver-Derived Signals Sequentially Reprogram Myeloid Enhancers to
  414 Initiate and Maintain Kupffer Cell Identity. *Immunity* **51**, 655-670 e658 (2019).
  415 <u>https://doi.org:10.1016/j.immuni.2019.09.002</u>
- 416 14 Krenkel, O. *et al.* Myeloid cells in liver and bone marrow acquire a functionally distinct
  417 inflammatory phenotype during obesity-related steatohepatitis. *Gut* 69, 551-563 (2020).
  418 https://doi.org:10.1136/gutjnl-2019-318382
- 419 15 Guilliams, M. *et al.* Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. *Cell* **185**, 379-396 e338 (2022).
  421 https://doi.org:10.1016/j.cell.2021.12.018
- 42216Govaere, O. *et al.* Transcriptomic profiling across the nonalcoholic fatty liver disease423spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci Transl Med 12424(2020). <a href="https://doi.org:10.1126/scitranslmed.aba4448">https://doi.org:10.1126/scitranslmed.aba4448</a>
- 425 17 Merle, N. S., Church, S. E., Fremeaux-Bacchi, V. & Roumenina, L. T. Complement
- 426 System Part I Molecular Mechanisms of Activation and Regulation. *Front Immunol* **6**, 427 262 (2015). https://doi.org:10.3389/fimmu.2015.00262

428	18	Kolev, M. & Kemper, C. Keeping It All Going-Complement Meets Metabolism. Front
429		Immunol 8, 1 (2017). <u>https://doi.org:10.3389/fimmu.2017.00001</u>
430	19	Zhao, J. et al. Association of complement components with the risk and severity of
431		NAFLD: A systematic review and meta-analysis. <i>Front Immunol</i> <b>13</b> , 1054159 (2022).
432		https://doi.org:10.3389/fimmu.2022.1054159
433	20	Segers, F. M. et al. Complement alternative pathway activation in human nonalcoholic
434		steatohepatitis. <i>PLoS One</i> <b>9</b> , e110053 (2014).
435		https://doi.org:10.1371/journal.pone.0110053
436	21	Markiewski, M. M. & Lambris, J. D. The role of complement in inflammatory diseases
437		from behind the scenes into the spotlight. Am J Pathol <b>171</b> , 715-727 (2007).
438		https://doi.org:10.2353/ajpath.2007.070166
439	22	Yadav, M. K. et al. Molecular basis of anaphylatoxin binding, activation, and signaling
440		bias at complement receptors. Cell 186, 4956-4973 e4921 (2023).
441		https://doi.org:10.1016/j.cell.2023.09.020
442	23	Flier, J. S., Cook, K. S., Usher, P. & Spiegelman, B. M. Severely impaired adipsin
443		expression in genetic and acquired obesity. <i>Science</i> <b>237</b> , 405-408 (1987).
444		https://doi.org:10.1126/science.3299706
445	24	Xu, Y. et al. Complement activation in factor D-deficient mice. Proc Natl Acad Sci U S A
446		98, 14577-14582 (2001). https://doi.org:10.1073/pnas.261428398
447	25	Lim, J. et al. C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic
448		dysfunction, and adipocyte and macrophage signaling. FASEB J 27, 822-831 (2013).
449		https://doi.org:10.1096/fj.12-220582
450	26	Polyzos, S. A., Kountouras, J. & Mantzoros, C. S. Adipokines in nonalcoholic fatty liver
451	20	disease. <i>Metabolism</i> <b>65</b> , 1062-1079 (2016).
452		https://doi.org:10.1016/j.metabol.2015.11.006
453	27	Han, J. & Zhang, X. Complement Component C3: A Novel Biomarker Participating in the
454	21	Pathogenesis of Non-alcoholic Fatty Liver Disease. <i>Front Med (Lausanne)</i> <b>8</b> , 653293
455		(2021). https://doi.org:10.3389/fmed.2021.653293
456	28	Lo, J. C. <i>et al.</i> Adipsin is an adipokine that improves beta cell function in diabetes. <i>Cell</i>
457	20	<b>158</b> , 41-53 (2014). <u>https://doi.org:10.1016/j.cell.2014.06.005</u>
458	29	Gomez-Banoy, N. <i>et al.</i> Adipsin preserves beta cells in diabetic mice and associates with
459	20	protection from type 2 diabetes in humans. <i>Nat Med</i> <b>25</b> , 1739-1747 (2019).
460		https://doi.org:10.1038/s41591-019-0610-4
461	30	Mamane, Y. <i>et al.</i> The C3a anaphylatoxin receptor is a key mediator of insulin resistance
462	00	and functions by modulating adipose tissue macrophage infiltration and activation.
463		<i>Diabetes</i> <b>58</b> , 2006-2017 (2009). <u>https://doi.org:10.2337/db09-0323</u>
464	31	Han, J. <i>et al.</i> Bone marrow-derived macrophage contributes to fibrosing steatohepatitis
465	01	through activating hepatic stellate cells. <i>J Pathol</i> <b>248</b> , 488-500 (2019).
466		https://doi.org:10.1002/path.5275
467	32	Boland, M. L. <i>et al.</i> Towards a standard diet-induced and biopsy-confirmed mouse model
468	52	of non-alcoholic steatohepatitis: Impact of dietary fat source. <i>World J Gastroenterol</i> <b>25</b> ,
469		4904-4920 (2019). <u>https://doi.org:10.3748/wjg.v25.i33.4904</u>
409	33	Hansen, H. H. <i>et al.</i> Human translatability of the GAN diet-induced obese mouse model
470	55	of non-alcoholic steatohepatitis. <i>BMC Gastroenterol</i> <b>20</b> , 210 (2020).
472 472	24	https://doi.org:10.1186/s12876-020-01356-2
473 474	34	Vacca, M. <i>et al.</i> An unbiased ranking of murine dietary models based on their proximity
474 475		to human metabolic dysfunction-associated steatotic liver disease (MASLD). <i>Nat Metab</i>
475 476	2E	(2024). <u>https://doi.org:10.1038/s42255-024-01043-6</u>
476	35	Uhlen, M. <i>et al.</i> Proteomics. Tissue-based map of the human proteome. <i>Science</i> <b>347</b> , 1260410 (2015) https://doi.org/10.1126/acianag.1260410
477		1260419 (2015). <u>https://doi.org:10.1126/science.1260419</u>

- 47836MacParland, S. A. *et al.* Single cell RNA sequencing of human liver reveals distinct479intrahepatic macrophage populations. *Nat Commun* **9**, 4383 (2018).480<u>https://doi.org:10.1038/s41467-018-06318-7</u>
- 48137Tabula Muris, C. *et al.* Single-cell transcriptomics of 20 mouse organs creates a Tabula482Muris. Nature 562, 367-372 (2018). <a href="https://doi.org/10.1038/s41586-018-0590-4">https://doi.org/10.1038/s41586-018-0590-4</a>
- Suppli, M. P. *et al.* Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. *Am J Physiol Gastrointest Liver Physiol* **316**, G462-G472 (2019).
  https://doi.org:10.1152/ajpgi.00358.2018
- 487 39 Ma, L. *et al.* Adipsin and Adipocyte-derived C3aR1 Regulate Thermogenic Fat in a Sex-488 dependent Fashion. *JCI Insight* (2024). <u>https://doi.org:10.1172/jci.insight.178925</u>
- 489 40
  490 40
  490 attenuates diet-induced obesity via activating inosine/A2aR pathway. *Cell Rep* 42, 112078 (2023). <u>https://doi.org:10.1016/j.celrep.2023.112078</u>
- 492 41 Li, X. *et al.* A new NASH model in aged mice with rapid progression of steatohepatitis 493 and fibrosis. *PLoS One* **18**, e0286257 (2023).
- 494 <u>https://doi.org:10.1371/journal.pone.0286257</u>
- 495 42
  496 Cumpelik, A. *et al.* Dynamic regulation of B cell complement signaling is integral to germinal center responses. *Nat Immunol* 22, 757-768 (2021).
  497 https://doi.org:10.1038/s41590-021-00926-0
- 498 43 Zhang, X., Goncalves, R. & Mosser, D. M. The isolation and characterization of murine 499 macrophages. *Curr Protoc Immunol* **Chapter 14**, 14 11 11-14 11 14 (2008). 500 https://doi.org:10.1002/0471142735.im1401s83
- 501